SubsidieMeestersTraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.
Projectdetails
TraffikGene-Tx: Targeted and Dynamic RNA Peptide Vehicles
Unmet Clinical Need and Problem
Rare and complex genetic diseases lead to significant disability, death, and associated cost burdens for society. Complex genetic diseases include cardiovascular diseases (CVD) and cancer, the two leading causes of death in the EU. Up to 36 million Europeans suffer from rare genetic diseases.
Nucleic acid therapeutics (NATs) represent a potential treatment, but they are hampered by the “delivery problem.” Systemically administered naked RNA is quickly degraded by endonucleases, can provoke adverse immune reactions, and has off-target toxicity. Viral and lipid nanoparticle (LNP) delivery vectors have toxic side effects and are difficult to produce and target.
The Solution
TraffikGene’s RNA delivery platform is:
- Safe: Biodegradable, non-immunogenic peptide carriers that cleave to avoid the detergent toxicity of LNPs.
- Targetable: Beyond the liver, to the spleen, lungs, and heart with excellent delivery to the cytosol.
- Scalable: Production is automated, simple, and cheap.
TraffikGene combines modular design with high-throughput screening, which will feed into AI-enhanced SAR-based predictive vehicle design. This will accelerate and de-risk NAT drug development.
The Project
TraffikGene will capitalize on the current breakthroughs in healthcare represented by NATs. RNA therapeutics (mRNA, saRNA, siRNA, lncRNA, miRNA) are now emerging, driven by the success of mRNA vaccines. TraffikGene will deliver them to the tissues where they are needed.
We aim to break new ground in the field of RNA, validate our delivery vehicles, and start developing our pipeline to advance to the preclinical trial stage with therapeutic RNAs. We aim to launch our company of customized peptide carriers for any RNA medicine with a proprietary flagship RNA-based immunotherapy.
Our products will bring many promising NATs to the market and help millions of patients while reducing healthcare costs.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.498.963 |
| Totale projectbegroting | € 2.498.963 |
Tijdlijn
| Startdatum | 1-6-2023 |
| Einddatum | 31-5-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSIDAD DE SANTIAGO DE COMPOSTELApenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
Smart RNA delivery for therapy and diagnosticThis project aims to develop peptide-based carriers for effective delivery of double-stranded RNA in cells, identifying candidates for potential commercial partnerships. | ERC Proof of... | € 150.000 | 2023 | Details |
Targeting long non-coding RNAs for novel treatment strategies in vascular diseasesThis project aims to identify and target specific long non-coding RNAs involved in vascular diseases using innovative RNA interference strategies to improve treatment outcomes. | ERC Consolid... | € 1.999.495 | 2023 | Details |
Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cellsPOLIRNA aims to develop a versatile platform for safe and efficient RNA delivery to target multiple cell types, enhancing preclinical research in cardiac and muscle-related diseases. | ERC Proof of... | € 150.000 | 2023 | Details |
nanoVAST: a novel, non- viral LNP for precision payload delivery of genome editors and other cargoThe project aims to develop the nanoVAST system for targeted RNA delivery to CD19+ B cells, enhancing specificity and efficiency while avoiding the drawbacks of current delivery methods. | ERC Proof of... | € 150.000 | 2022 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.
Smart RNA delivery for therapy and diagnostic
This project aims to develop peptide-based carriers for effective delivery of double-stranded RNA in cells, identifying candidates for potential commercial partnerships.
Targeting long non-coding RNAs for novel treatment strategies in vascular diseases
This project aims to identify and target specific long non-coding RNAs involved in vascular diseases using innovative RNA interference strategies to improve treatment outcomes.
Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cells
POLIRNA aims to develop a versatile platform for safe and efficient RNA delivery to target multiple cell types, enhancing preclinical research in cardiac and muscle-related diseases.
nanoVAST: a novel, non- viral LNP for precision payload delivery of genome editors and other cargo
The project aims to develop the nanoVAST system for targeted RNA delivery to CD19+ B cells, enhancing specificity and efficiency while avoiding the drawbacks of current delivery methods.